Overview Phio Pharmaceuticals Corp. ( Phio , we , our or the Company ) is a clinical stage biopharmaceuticalcompany whose proprietary INTASYL small interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. We are developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the bodys ability to fight cancer, without the need for specialized formulations or drug delivery systems. We are commi...
Q2 FY2026 — expected 2026-09-15
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-05 | 2025-12-31 | 0001437749-26-007078 | EDGAR | 47K words |
| 2025-03-31 | 2024-12-31 | 0001683168-25-002134 | EDGAR | — |
| 2024-04-01 | 2023-12-31 | 0001683168-24-002021 | EDGAR | — |
| 2023-03-22 | 2022-12-31 | 0001683168-23-001678 | EDGAR | — |
| 2022-03-22 | 2021-12-31 | 0001683168-22-001833 | EDGAR | — |
| 2021-03-25 | 2020-12-31 | 0001683168-21-001062 | EDGAR | — |
| 2020-03-26 | 2019-12-31 | 0001683168-20-000969 | EDGAR | — |
| 2019-03-27 | 2018-12-31 | 0001683168-19-000795 | EDGAR | — |
| 2018-03-26 | 2017-12-31 | 0001193125-18-096053 | EDGAR | — |
| 2017-03-30 | 2016-12-31 | 0001193125-17-102730 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-13 | 2025-09-30 | 0001437749-25-034857 | EDGAR | 18K words |
| 2025-08-14 | 2025-06-30 | 0001683168-25-006174 | EDGAR | — |
| 2025-05-15 | 2025-03-31 | 0001683168-25-003719 | EDGAR | — |
| 2024-11-14 | 2024-09-30 | 0001683168-24-008120 | EDGAR | — |
| 2024-08-14 | 2024-06-30 | 0001683168-24-005706 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0001683168-24-003175 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0001683168-23-007809 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0001683168-23-005514 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0001683168-23-003213 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0001683168-22-007528 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0001683168-22-005565 | EDGAR | — |
| 2022-05-12 | 2022-03-31 | 0001683168-22-003516 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-30 | 0001437749-26-010164 | EDGAR | 1K words |
| 2026-03-05 | 0001437749-26-007071 | EDGAR | — |
| 2026-02-18 | 0001437749-26-004542 | EDGAR | — |
| 2026-02-10 | 0001437749-26-003575 | EDGAR | — |
| 2026-01-20 | 0001437749-26-001500 | EDGAR | — |
| 2025-12-23 | 0001437749-25-038607 | EDGAR | — |
| 2025-11-25 | 0001437749-25-036329 | EDGAR | — |
| 2025-11-13 | 0001437749-25-034848 | EDGAR | — |
| 2025-11-06 | 0001437749-25-033600 | EDGAR | — |
| 2025-11-03 | 0001437749-25-032662 | EDGAR | — |
327 total filings indexed. 295 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001533040 |
| Ticker | PHIO |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.phiopharma.com |
| Listed | 2012-05-10 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report